Kajian klinikal Migrain di Illinois
6 kajian untuk Migrain sedang mencari peserta di lokasi di Illinois.
Bandar di Illinois
Teks kajian rasmi (Bahasa Inggeris)
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
- Chicago Headache Center & Research Institute, Chicago
- AMR-Baber Research Inc, Naperville
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT04743141Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Chicago Headache Center & Research Institute, Chicago
- AMR-Baber Research Inc, Naperville
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT04649242Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Chicago Headache Center & Research Institute /ID# 248625, Chicago
- Ascension Saint Alexius /ID# 275261, Hoffman Estates
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05125302A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Cedar Crosse Research Center, Chicago
- Chicago Headache Center & Research Institute, Chicago
- Healthcare Research Network II, LLC, Flossmoor
- dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07645924Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
- Chicago Headache Center & Research Inst /ID# 272345, Naperville
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Feb 2026 · NCT07310290Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
- Advocate Christ Medical Center Emergency Department, Oak Lawn
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jan 2026 · NCT06904287Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.